Q1 2025 Merck KGaA Earnings Call Transcript
Key Points
- Merck KGaA (MKGAF) achieved profitable growth across all three business sectors in Q1 2025, with group revenues increasing by 3% organically and EBITDA pre rising by 6%.
- Process Solutions showed remarkable progress, crossing into double-digit growth with an 11% increase in Q1, driven by strong order intake and a book-to-bill ratio comfortably above 1.
- Healthcare delivered organic sales growth of 3.4%, supported by strong performance in the CM&E portfolio and solid growth of Erbitux and Mavenclad.
- Electronics experienced positive organic sales development, particularly in Semiconductor Materials, which contributed to a 2% growth in the Semiconductor Solutions business.
- Merck KGaA (MKGAF) has taken proactive measures to mitigate potential impacts from tariffs and currency fluctuations, demonstrating adaptability in a challenging macroeconomic environment.
- Operating cash flow decreased by EUR556 million, primarily due to an increase in receivables and inventories, higher bonus payments, and higher tax payments.
- Science & Lab Solutions (SLS) faced a decline in sales by 2.5% organically, impacted by US policy changes affecting academic and government lab spending and a cautious pharma research spending environment.
- Life Science Services saw a 6.2% organic decline in sales, mainly driven by CDMO activities affected by funding constraints and unfavorable project phasing.
- The Electronics sector's DS&S business experienced a low double-digit percentage decline due to customer projects being pushed out further.
- Merck KGaA (MKGAF) adjusted its 2025 guidance corridors due to currency movements, particularly a weak US dollar, and potential tariff impacts, reflecting ongoing macroeconomic volatility.
Dear ladies and gentlemen, welcome to the Merck investor and analyst conference call on first quarter 2025. (Operator Instructions)
I am now handing over to Florian Schraeder, Head of Investor Relations, who will lead you through this conference. Please go ahead, sir.
Thank you so much, Heidi. And a very warm welcome to this Merck Q1 '25 results call. My name is Florian Schraeder. I'm the Head of Investor Relations here at Merck.
I'm delighted to be joined today by Belén Garijo, our Group CEO; as well as Helene von Roeder, our Group CFO. For the Q&A part of this call, we will also have Matthias Heinzel, CEO, Life Science; Jean-Charles Wirth, Designated CEO, Life Science; Peter Guenter, CEO, Healthcare; Danny Bar-Zohar, Designated CEO, Healthcare; as well as Kai Beckmann, CEO, Electronics.
In the first couple of minutes of this call, we would like to guide you through the key slides of the presentation. After that, we will be more than happy to take your questions.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
